Xuewu T. Liang

State Key Laboratory Of Drug Research
Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Discovery of Novel LRPPRC Inhibitors Featuring a Biphenyl-Acylhydrazone Scaffold with Potent Broad-Spectrum Antitumor Activity.

Discovery of Novel LRPPRC Inhibitors Featuring a Biphenyl-Acylhydrazone Scaffold with Potent Broad-Spectrum Antitumor Activity.

Journal: Journal of medicinal chemistry

Published: July 13, 2026

Identification of a small-molecule targeting PLAGL2 DNA-binding domain inhibits extracellular matrix formation and enhances lenvatinib sensitivity in hepatocellular carcinoma.

Identification of a small-molecule targeting PLAGL2 DNA-binding domain inhibits extracellular matrix formation and enhances lenvatinib sensitivity in hepatocellular carcinoma.

Journal: Acta pharmaceutica Sinica. B

Published: March 16, 2025

Discovery of Novel RNA Demethylase FTO Inhibitors Featuring an Acylhydrazone Scaffold with Potent Antileukemia Activity.

Discovery of Novel RNA Demethylase FTO Inhibitors Featuring an Acylhydrazone Scaffold with Potent Antileukemia Activity.

Journal: Journal of medicinal chemistry

Published: January 17, 2025

Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies.

Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies.

Journal: Journal of medicinal chemistry

Published: August 23, 2024

Discovery of Novel Pyrimidine-Based Derivatives as Nav1.2 Inhibitors with Efficacy in Mouse Models of Epilepsy.

Discovery of Novel Pyrimidine-Based Derivatives as Nav1.2 Inhibitors with Efficacy in Mouse Models of Epilepsy.

Journal: Journal of medicinal chemistry

Published: July 22, 2024

Discovery and Optimization of Novel Nonbile Acid FXR Agonists as Preclinical Candidates for the Treatment of Inflammatory Bowel Disease.

Discovery and Optimization of Novel Nonbile Acid FXR Agonists as Preclinical Candidates for the Treatment of Inflammatory Bowel Disease.

Journal: Journal of medicinal chemistry

Published: March 28, 2024

Identification and experimental validation of PYCARD as a crucial PANoptosis-related gene for immune response and inflammation in COPD.

Identification and experimental validation of PYCARD as a crucial PANoptosis-related gene for immune response and inflammation in COPD.

Journal: Apoptosis : an international journal on programmed cell death

Published: March 15, 2024

Development of Potent MALT1 Inhibitors Featuring a Novel "2-Thioxo-2,3-dihydrothiazolo[4,5-d]pyrimidin-7(6H)-one" Scaffold for the Treatment of B Cell Lymphoma.

Development of Potent MALT1 Inhibitors Featuring a Novel "2-Thioxo-2,3-dihydrothiazolo[4,5-d]pyrimidin-7(6H)-one" Scaffold for the Treatment of B Cell Lymphoma.

Journal: Journal of medicinal chemistry

Published: February 13, 2024

Construction of Diversified Penta-Spiro-Heterocyclic and Fused-Heterocyclic Frameworks with Potent Antitumor Activity.

Construction of Diversified Penta-Spiro-Heterocyclic and Fused-Heterocyclic Frameworks with Potent Antitumor Activity.

Journal: Chemistry (Weinheim an der Bergstrasse, Germany)

Published: September 21, 2023

Construction of Diversified Penta-Spiro-Heterocyclic and Fused-Heterocyclic Frameworks with Potent Antitumor Activity.

Construction of Diversified Penta-Spiro-Heterocyclic and Fused-Heterocyclic Frameworks with Potent Antitumor Activity.

Journal: Chemistry (Weinheim an der Bergstrasse, Germany)

Published: May 20, 2023

Structure-based drug discovery of novel fused-pyrazolone carboxamide derivatives as potent and selective AXL inhibitors.

Structure-based drug discovery of novel fused-pyrazolone carboxamide derivatives as potent and selective AXL inhibitors.

Journal: Acta pharmaceutica Sinica. B

Published: April 13, 2023

The new direction of drug development: Degradation of undruggable targets through targeting chimera technology.

The new direction of drug development: Degradation of undruggable targets through targeting chimera technology.

Journal: Medicinal research reviews

Published: November 30, 2022

Showing 1-12 of 31

Last Updated: 09/26/2026